Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

[1]  Nico Pfeifer,et al.  Combination therapy with anti-HIV-1 antibodies maintains viral suppression , 2018, Nature.

[2]  P. Volberding,et al.  Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA , 2018, Journal of Virology.

[3]  Jerome H. Kim,et al.  Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection , 2018, Nature Medicine.

[4]  Xu G. Yu,et al.  Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals , 2018, PLoS pathogens.

[5]  M. Proschan,et al.  A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection , 2017, Science Translational Medicine.

[6]  M. Carrington,et al.  Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption , 2017, Pathogens & immunity.

[7]  M. Nussenzweig,et al.  Early antibody therapy can induce long-lasting immunity to SHIV , 2017, Nature.

[8]  G. Learn,et al.  Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. , 2016, The New England journal of medicine.

[9]  J. Ananworanich,et al.  HIV DNA Set Point is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early ART , 2016, EBioMedicine.

[10]  Richard Jefferys,et al.  International AIDS Society global scientific strategy: towards an HIV cure 2016 , 2016, Nature Medicine.

[11]  Nico Pfeifer,et al.  HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption , 2016, Nature.

[12]  Nico Pfeifer,et al.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 , 2016, Science.

[13]  Jerome H. Kim,et al.  Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand. , 2016, The New England journal of medicine.

[14]  J. Mascola,et al.  A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges , 2016, Nature.

[15]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[16]  J. Mascola,et al.  Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV‐1 human monoclonal antibody VRC01 in healthy adults , 2015, Clinical and experimental immunology.

[17]  J. Mascola,et al.  Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs , 2015, Journal of Virology.

[18]  R. Phillips,et al.  Immunological biomarkers predict HIV-1 viral rebound after treatment interruption , 2015, Nature Communications.

[19]  Anthony D. Kelleher,et al.  HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission , 2015, PLoS pathogens.

[20]  Jerome H. Kim,et al.  Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection , 2015, AIDS.

[21]  A. Haase,et al.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption , 2015, Proceedings of the National Academy of Sciences.

[22]  Angela R. McLean,et al.  Structured Observations Reveal Slow HIV-1 CTL Escape , 2015, PLoS genetics.

[23]  M. Carrington,et al.  HIV-1 DNA predicts disease progression and post-treatment virological control , 2014, eLife.

[24]  T. Chun,et al.  Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir , 2014, Proceedings of the National Academy of Sciences.

[25]  E. Rosenberg,et al.  Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells , 2014, Journal of Virology.

[26]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[27]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[28]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[29]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[30]  M A Nowak,et al.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.